Zytiga alone (abiraterone + prednisone) suppresses testosterone levels as effectively as Zytiga + ADT in mCRPC patients

Researchers at the Univ. of Minnesota conducted a retrospective study of 57 consecutive men with mCRPC followed for one year and found that testosterone levels were suppressed equally whether the men were given Zytiga alone or Zytiga plus ADT drugs such as Lupron and Firmagon.  This can provide substantial cost savings for the patients and for society.  You can read the full 2019 ASCO abstract here: http://abstracts.asco.org/239/AbstView_239_266583.html